Overview MK3207 for Treatment of Acute Migraines (3207-005) Status: Completed Trial end date: 2009-01-01 Target enrollment: Participant gender: Summary The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.